Equities research analysts expect Incyte Co. (NASDAQ:INCY) to announce earnings per share of $0.12 for the current quarter, according to Zacks. Thirteen analysts have made estimates for Incyte’s earnings, with the highest EPS estimate coming in at $0.33 and the lowest estimate coming in at ($0.01). Incyte reported earnings per share of ($0.06) during the same quarter last year, which would suggest a positive year over year growth rate of 300%. The firm is expected to announce its next quarterly earnings report on Tuesday, August 7th.
On average, analysts expect that Incyte will report full-year earnings of $0.72 per share for the current year, with EPS estimates ranging from ($0.19) to $1.72. For the next year, analysts expect that the firm will post earnings of $1.70 per share, with EPS estimates ranging from $0.07 to $3.63. Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Incyte.
Incyte (NASDAQ:INCY) last released its earnings results on Tuesday, May 1st. The biopharmaceutical company reported ($0.01) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.09) by $0.08. The company had revenue of $382.28 million for the quarter, compared to the consensus estimate of $384.03 million. Incyte had a negative return on equity of 0.74% and a negative net margin of 10.90%. Incyte’s quarterly revenue was down .5% compared to the same quarter last year. During the same period in the previous year, the business earned $0.14 earnings per share.
NASDAQ:INCY traded up $1.19 on Tuesday, reaching $67.83. 1,768,573 shares of the company’s stock traded hands, compared to its average volume of 2,906,210. The company has a quick ratio of 3.84, a current ratio of 3.86 and a debt-to-equity ratio of 0.01. The stock has a market cap of $14.38 billion, a PE ratio of 105.98 and a beta of 0.72. Incyte has a 12 month low of $60.22 and a 12 month high of $140.11.
In other news, President Herve Hoppenot purchased 15,000 shares of the stock in a transaction that occurred on Wednesday, May 2nd. The stock was purchased at an average price of $60.94 per share, for a total transaction of $914,100.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider David W. Gryska sold 1,952 shares of the business’s stock in a transaction that occurred on Wednesday, February 21st. The shares were sold at an average price of $85.56, for a total value of $167,013.12. Following the completion of the sale, the insider now owns 12,922 shares of the company’s stock, valued at approximately $1,105,606.32. The disclosure for this sale can be found here. Insiders have sold 83,910 shares of company stock valued at $5,328,920 in the last 90 days. Company insiders own 17.20% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Addison Capital Co boosted its holdings in shares of Incyte by 9.5% in the fourth quarter. Addison Capital Co now owns 6,632 shares of the biopharmaceutical company’s stock valued at $628,000 after purchasing an additional 574 shares during the period. New Mexico Educational Retirement Board raised its stake in Incyte by 3.8% in the fourth quarter. New Mexico Educational Retirement Board now owns 16,400 shares of the biopharmaceutical company’s stock worth $1,553,000 after buying an additional 600 shares in the last quarter. Greenwood Capital Associates LLC raised its stake in Incyte by 35.9% in the fourth quarter. Greenwood Capital Associates LLC now owns 2,719 shares of the biopharmaceutical company’s stock worth $258,000 after buying an additional 718 shares in the last quarter. Tyers Asset Management LLC raised its stake in Incyte by 22.0% in the first quarter. Tyers Asset Management LLC now owns 4,976 shares of the biopharmaceutical company’s stock worth $415,000 after buying an additional 896 shares in the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec raised its stake in Incyte by 34.6% in the first quarter. Caisse DE Depot ET Placement DU Quebec now owns 3,500 shares of the biopharmaceutical company’s stock worth $292,000 after buying an additional 900 shares in the last quarter. Hedge funds and other institutional investors own 93.55% of the company’s stock.
Incyte Company Profile
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States. It offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and ICLUSIG, a kinase inhibitor for the treatment of chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.